New viral vaccines

Virology

Volumn 344, Issue 1, 2006, Pages 240-249

  Arvin, Ann M ^a   Greenberg, Harry B ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; INFLUENZA VACCINE; PAPILLOMA VIRUS VACCINE; ROTAVIRUS VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

CHICKENPOX; DRUG POTENCY; EPIDEMIC; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; VACCINE PRODUCTION; VARICELLA ZOSTER VIRUS; VERRUCA VULGARIS; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; HERPESVIRUS 3, HUMAN; HERPESVIRUS VACCINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; PAPILLOMAVIRIDAE; ROTAVIRUS; ROTAVIRUS VACCINES; VIRAL VACCINES;

DNA VIRUSES; HEPATITIS C VIRUS; HUMAN HERPESVIRUS 3; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS; INFLUENZAVIRUS A; INFLUENZAVIRUS B; PAPILLOMAVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS; RNA VIRUSES; ROTAVIRUS; VARIOLA VIRUS;

EID: 29244482595     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2005.09.057     Document Type: Review

References (77)

1. A.M. Arvin Varicella vaccine: genesis, efficacy, and attenuation Virology 284 2 2001 153 158
2. A.M. Arvin Varicella-zoster virus D.M. Knipe P. Howley Fields' Virology 2001 Lippincott-Williams and Wilkins Philadelphia 2731 2768
3. R.B. Belshe Current status of live attenuated influenza virus vaccine in the US Virus Res. 103 1-2 2004 177 185
4. R.B. Belshe Influenza vaccines-Live S.A. Plotkin W. Ornstein W. Vaccines 2004 Saunders Philadelphia 371
5. R.B. Belshe, and P.M. Mendelman The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children N. Engl. J. Med. 338 20 1998 1405 1412
6. R.B. Belshe, and W.C. Gruber Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine J. Pediatr. 136 2 2000 168 175
7. R.B. Belshe, and W.C. Gruber Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine J. Infect. Dis. 181 3 2000 1133 1137
8. S.E. Blutt, and C.D. Kirkwood Rotavirus antigenaemia and viraemia: a common event? Lancet 362 9394 2003 1445 1449
9. F.X. Bosch, and A. Lorincz The causal relation between human papillomavirus and cervical cancer J. Clin. Pathol. 55 4 2002 244 265
10. P. Bruhl, and A. Kerschbaum Humoral and cell-mediated immunity to vero cell-derived influenza vaccine Vaccine 19 9-10 2000 1149 1158
11. J.J. Carter, and L.A. Koutsky Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection J. Infect. Dis. 181 6 2000 1911 1919
12. S. Chellappan, and V.B. Kraus Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product Proc. Natl. Acad. Sci. U.S.A. 89 10 1992 4549 4553
13. H.F. Clark, and D.I. Bernstein Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants J. Pediatr. 144 2 2004 184 190
14. B. De Vos, and T. Vesikari A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis Pediatr. Infect Dis. J. 23 Suppl. 10 2004 S179 S182
15. P.H. Dennehy, and R.C. Brady Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine Pediatr. Infect Dis. J. 24 6 2005 481 488
16. Dubin, G., Zahaf, T., C.B., Quint, W., Martin, M., Jenkins, D., 2005. Cross-Protection Against Persistent HPV Infection, Abnormal Cytology and CIN Associated with HPV-16 and 18 Related HPV Types by a HPV 16/18 L1 Virus-Like Particle Vaccine [abstract]. 22nd International Papillomavirus Conference and Clinical Workshop.
17. R.T. Emeny, and C.M. Wheeler Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine J. Virol. 76 15 2002 7832 7842
18. M.K. Estes, and G. Kang Pathogenesis of rotavirus gastroenteritis Novartis Found. Symp. 238 2001 82 96 (Discussion 96-100)
19. J. Ferlay, B.F. Pisani, and P.D.M. Parkin GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalance Worldwide 2004 IARC Press Lyon
20. M.A. Franco, and H.B. Greenberg Challenges for rotavirus vaccines Virology 281 2 2001 153 155
21. I.H. Frazer Immunology of papillomavirus infection Curr. Opin. Immunol. 8 4 1996 484 491
22. K. Fukuda Influenza vaccines-inactivated S.A. Plotkin W. Ornstein W. Vaccines 2004 Saunders Philadelphia 339
23. Gershon, A.A., 2001. Live-attenuated varicella vaccine. Infect Dis. Clin. North Am. 15 (1) 65-81, viii.
24. D.H. Gilden, and B.K. Kleinschmidt-DeMasters Neurologic complications of the reactivation of varicella-zoster virus N. Engl. J. Med. 342 9 2000 635 645
25. M.E. Halloran, and I.M. Longini Jr. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures Am. J. Epidemiol. 158 4 2003 305 311
26. S.A. Halperin, and B. Smith Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children Vaccine 20 7-8 2002 1240 1247
27. D.M. Harper, and E.L. Franco Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 9447 2004 1757 1765
28. A. Hata, and H. Asanuma Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants N. Engl. J. Med. 347 1 2002 26 34
29. A. Hayward, and M. Levin Varicella-zoster virus-specific immunity after herpes zoster J. Infect. Dis. 163 4 1991 873 875
30. X.S. He, and K. Mahmood Analysis of the frequencies and of the memory T cell phenotypes of human CD8+ T cells specific for influenza A viruses J. Infect. Dis. 187 7 2003 1075 1084
31. X.S. He, and M. Draghi T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus J. Clin. Invest. 114 12 2004 1812 1819
32. E. Hoffmann, and G. Neumann A DNA transfection system for generation of influenza A virus from eight plasmids Proc. Natl. Acad. Sci. U.S.A. 97 11 2000 6108 6113
33. E. Hoffmann, and K. Mahmood Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66 J. Virol. 79 17 2005 11014 11021
34. R. Hopfl, and K. Heim Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7 Lancet 356 9246 2000 1985 1986
35. T. Horimoto, and Y. Kawaoka Influenza: lessons from past pandemics, warnings from current incidents Nat. Rev., Microbiol. 3 8 2005 591 600
36. V.P. Hsu, and M.A. Staat Use of active surveillance to validate international classification of diseases code estimates of rotavirus hospitalizations in children Pediatrics 115 1 2005 78 82
37. W.F. Jarrett, and B.W. O'Neil Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination Vet. Rec. 126 18 1990 449 452
38. H. Jin, and B. Lu Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60 Virology 306 1 2003 18 24
39. G. Kemble, and H. Greenberg Novel generations of influenza vaccines Vaccine 21 16 2003 1789 1795
40. R. Kirnbauer, and F. Booy Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic Proc. Natl. Acad. Sci. U.S.A. 89 24 1992 12180 12184
41. R. Kirnbauer, and J. Taub Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles J. Virol. 67 12 1993 6929 6936
42. M. Koopmans, and D. Brown Seasonality and diversity of Group A rotaviruses in Europe Acta Paediatr., Suppl. 88 426 1999 14 19
43. M. Kosek, and C. Bern The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000 Bull. World Health Organ. 81 3 2003 197 204
44. L.A. Koutsky, and K.A. Ault A controlled trial of a human papillomavirus type 16 vaccine N. Engl. J. Med. 347 21 2002 1645 1651
45. C.C. Ku, and J. Besser Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model J. Virol. 79 5 2005 2651 2658
46. M.J. Levin, and J.G. Smith Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine J. Infect. Dis. 188 9 2003 1336 1344
47. MMWR Morbidity and Mortality Weekly Report, Centers for Disease Control 2004
48. K. Munger, and A. Baldwin Mechanisms of human papillomavirus-induced oncogenesis J. Virol. 78 21 2004 11451 11460
49. N. Munoz, and F.X. Bosch Against which human papillomavirus types shall we vaccinate and screen? The international perspective Int. J. Cancer 111 2 2004 278 285
50. T.V. Murphy, and P.M. Gargiullo Intussusception among infants given an oral rotavirus vaccine N. Engl. J. Med. 344 8 2001 564 572
51. B.R. Murphy, and D.M. Morens Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions J. Infect. Dis. 187 8 2003 1301 1308
52. G. Neumann, and T. Watanabe Generation of influenza A viruses entirely from cloned cDNAs Proc. Natl. Acad. Sci. U.S.A. 96 16 1999 9345 9350
53. H.Q. Nguyen, and A.O. Jumaan Decline in mortality due to varicella after implementation of varicella vaccination in the United States N. Engl. J. Med. 352 5 2005 450 458
54. K.L. Nichol, and P.M. Mendelman Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial JAMA 282 2 1999 137 144
55. P.A. Offit The future of rotavirus vaccines Semin. Pediatr. Infect Dis. 13 3 2002 190 195
56. M. O'Ryan, and V. Prado A millennium update on pediatric diarrheal illness in the developing world Semin. Pediatr. Infect Dis. 16 2 2005 125 136
57. M.N. Oxman, and M.J. Levin A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N. Engl. J. Med. 352 22 2005 2271 2284
58. P. Palese, and A. Garcia-Sastre Influenza vaccines: present and future J. Clin. Invest. 110 1 2002 9 13
59. U.D. Parashar, and E.G. Hummelman Global illness and deaths caused by rotavirus disease in children Emerg. Infect Dis. 9 5 2003 565 572
60. I. Perez-Schael, and M.J. Guntinas Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela N. Engl. J. Med. 337 17 1997 1181 1187
61. K.B. Phua, and S.H. Quak Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants J. Infect. Dis. 192 Suppl. 1 2005 S6 S16
62. A. Podda The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine Vaccine 19 17-19 2001 2673 2680
63. N. Santos, and Y. Hoshino Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine Rev. Med. Virol. 15 1 2005 29 56
64. M. Scheffner, and J.M. Huibregtse The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 Cell 75 3 1993 495 505
65. F.H. Sillman, and S. Sentovich Ano-genital neoplasia in renal transplant patients Ann. Transplant. 2 4 1997 59 66
66. L. Simonsen, and D. Morens Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception Lancet 358 9289 2001 1224 1229
67. L. Simonsen, and C. Viboud More on RotaShield and Intussusception: the role of age at the time of vaccination J. Infect. Dis. 192 Suppl. 1 2005 S36 S43
68. R.J. Slebos, and M.H. Lee p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein Proc. Natl. Acad. Sci. U.S.A. 91 12 1994 5320 5324
69. M. Thomas, and G. Matlashewski Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation Oncogene 13 2 1996 265 273
70. F.R. Velazquez, and D.O. Matson Rotavirus infections in infants as protection against subsequent infections N. Engl. J. Med. 335 14 1996 1022 1028
71. T. Vesikari, and A. Karvonen Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants Pediatr. Infect Dis. J. 23 10 2004 937 943
72. J.M. Walboomers, and M.V. Jacobs Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J. Pathol. 189 1 1999 12 19
73. M.J. Welters, and A. de Jong Frequent display of human papillomavirus type 16 E6-specific memory T-Helper cells in the healthy population as witness of previous viral encounter Cancer Res. 63 3 2003 636 641
74. P. Wright Orthomyxoviruses D.M. Knipe P. Howley Fields Virology 2002 Williams and Wilkins Lippincott
75. L. Zerboni, and C.C. Ku Varicella-zoster virus infection of human dorsal root ganglia in vivo Proc. Natl. Acad. Sci. U.S.A. 102 18 2005 6490 6495
76. J. Zhou, and X.Y. Sun Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles Virology 185 1 1991 251 257
77. H. zur Hausen Papillomaviruses and cancer: from basic studies to clinical application Nat. Rev., Cancer 2 5 2002 342 350